AstraZeneca PLC (AZN)vsEmergent Biosolutions Inc (EBS)
AZN
AstraZeneca PLC
$185.95
-1.66%
HEALTHCARE · Cap: $282.69B
EBS
Emergent Biosolutions Inc
$8.07
-4.38%
HEALTHCARE · Cap: $419.99M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8830% more annual revenue ($60.44B vs $676.80M). AZN leads profitability with a 17.2% profit margin vs -1.3%. EBS appears more attractively valued with a PEG of 0.38. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
EBS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+63.5%
Fair Value
$30.24
Current Price
$8.07
$22.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
ROE of -1.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : EBS
The strongest argument for EBS centers on PEG Ratio, Price/Book. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : EBS
The primary concerns for EBS are Altman Z-Score, Market Cap, Debt/Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while EBS is a turnaround play — different risk/reward profiles.
EBS carries more volatility with a beta of 2.33 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 48/100), backed by strong 17.2% margins and 12.5% revenue growth. EBS offers better value entry with a 63.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Emergent Biosolutions Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?